3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Lung Neoplasms
5
Carcinoma, Transitional Cell
4
Carcinoma, Renal Cell
4
Triple Negative Breast Neoplasms
3
Small Cell Lung Carcinoma
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Carcinoma, Hepatocellular
3
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Sarcoma, Kaposi
1
Recurrence
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Metastatic Squamous Non-Small Cell Lung Carcinoma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
HIV Infections
1
Endometrial Neoplasms
1
Carcinoma, Neuroendocrine
1
Carcinoma, Medullary
1
Carcinoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Carboplatin
24
Pemetrexed
18
Cisplatin
17
Paclitaxel
14
pembrolizumab
13
Gemcitabine
8
osimertinib
7
durvalumab
6
Docetaxel
6
Nivolumab
5
Erlotinib Hydrochloride
5
130-nm albumin-bound paclitaxel
5
capmatinib
3
brigatinib
3
anlotinib
3
Gefitinib
3
Drug Therapy
3
vosaroxin
2
volociximab
2
sintilimab
2
pralsetinib
2
ensartinib
2
atezolizumab
2
aflibercept
2
Surgical Procedures, Operative
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiation
2
Oncolytic Virotherapy
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
cabozantinib
×
Thoracic
×
Clear all
NCT04151563
2023-12-19
CheckMate 79X
Bristol-Myers Squibb
Phase 1/2
Withdrawn